Block Admission and ISIN update

    Medgenics, Inc.
                         ("Medgenics" or the "Company")
                                        
                         Block Admission and ISIN update
                                        
4 December 2007

Medgenics  is  the  holding company of a clinical trial stage  biopharmaceutical
group  with  operations primarily in Israel and which is  planning  to  commence
testing the safety and efficacy of its proprietary Biopump in 2008.  The Company
has  made an application to the London Stock Exchange for a block admission  (in
relation  to  the  Company's outstanding Warrants and Options  under  the  Share
Incentive  Plan)  to  trading on AIM on 4 December 2007  for  20,818,683  Common
Shares  of  US  $0.0001 each which are subject to Regulation S restrictions  and
which represent 20 per cent. of the Company's issued Common Shares on Admission.

The  Company  will notify the public through an RNS announcement the information
required in Schedule Eight of the AIM Rules immediately following 30 June and 31
December  in each year.  The next notification will be for the period 4 December
2007 to 31 December 2007.

The  Company is also announcing that all of its Common Shares on Admission  will
be  issued under the ISIN USU582411075 and subject to Regulation S restrictions.
This is a change of ISIN from the number reported in the Admission Document.


Enquiries:

Dr. Andrew L.           [phone]    Medgenics, Inc.                       President and CEO
Pearlman                                         

James Pinner or         [phone]   Blomfield Corporate Finance Limited   Nominated Adviser
Alan MacKenzie                       
                                  
                                  
Peter Manfield or       [phone]   SVS Securities plc                    Brokers
Ian Callaway                 
                                  
Jonathan Shillington or [phone]   Citigate Dewe Rogerson                Public Relations
Mark Swallow or
Chris Gardner